Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Stuttgart - Delayed Quote • EUR Dr Reddy's Laboratories Ltd (RDDA.SG) Follow Compare 12.40 -0.10 (-0.80%) At close: February 27 at 3:58:19 PM GMT+1 Comparisons Indicators Technicals Corporate Events Line Candle Baseline Mountain Bar Step Baseline Delta HLC Wave Scatterplot Histogram Range Channel Colored Line Colored Mountain Colored Step Colored Bar Colored HLC Volume Candle Hollow Candle Step Mountain Verex Line Vertex Step Vertex Mountain Vertex Baseline Delta Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for RDDA.SG 1D 5D -1.59% 1M -3.88% 3M -5.34% 6M -15.07% YTD -16.78% 1Y -13.89% 5Y 60.62% All 412.82% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours 1 day 1 week 1 month 3 months Recent News: RDDA.SG View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. Dr. Reddy’s Q3 & 9MFY25 Financial Results Dr. Reddy’s Laboratories Allocates Equity Shares to Employees Dr. Reddy’s Boosts Workforce with Equity Allotment Dr. Reddy’s Launches Innovative Cancer Drug in India Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market Dr. Reddy’s Gains Strong Rating Amid Robust Growth Dr. Reddy’s Q2 & H1FY25 Financial Results Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year Related Tickers SNT.AX Syntara Limited 0.0800 -3.61% ANIP ANI Pharmaceuticals, Inc. 54.58 -0.78% AMPH Amphastar Pharmaceuticals, Inc. 31.49 +0.90% ALVO Alvotech 11.46 -2.63% VTRS Viatris Inc. 9.53 -15.21% TEVA Teva Pharmaceutical Industries Limited 16.32 -2.74%